Introduction

Cardiac implantable electronic devices (CIEDs) have been a cornerstone of modern cardiology for decades, saving millions of lives through pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. Yet these life-sustaining systems depend on a single weakness: the batteries that power them. Current lithium-iodine and lithium-manganese dioxide cells typically last between 5 and 10 years, after which patients must undergo a surgical procedure to replace the entire device. This not only carries risks of infection, bleeding, and anesthesia complications but also imposes a significant economic burden on healthcare systems. Wireless power transfer (WPT) technologies are emerging as a transformative solution that could eliminate the need for periodic battery replacement, reduce surgical interventions, and enable next-generation implant designs with greater functionality.

Recent advances in inductive coupling, resonant power transfer, radiofrequency (RF) energy harvesting, and ultrasound-based systems have brought WPT closer to clinical reality. By delivering energy safely and efficiently through the skin and tissue, these technologies promise to free patients from the constraints of battery longevity. This article explores the current state of wireless power for cardiac implants, the engineering challenges that remain, and the trajectory toward a future where battery surgery is a thing of the past.

The Critical Need for Wireless Power in Cardiac Implants

Despite their proven efficacy, conventional CIEDs are plagued by the fundamental limitation of their power source. Each replacement surgery introduces a window of vulnerability for the patient. According to data from the National Cardiovascular Data Registry, the incidence of complications such as pocket hematoma, device infection, and lead damage during replacement procedures ranges from 2% to 5%, with higher rates in elderly or immunocompromised populations. Beyond clinical risks, the financial cost is substantial: a single pacemaker replacement can exceed $30,000 when factoring in hospital stay, surgeon fees, and device costs.

Moreover, battery depletion often occurs unpredictably. Although manufacturers provide estimated longevity curves, actual battery life varies with pacing demand, device programming, and battery chemistry. A device that relies on a finite power source cannot support advanced features such as continuous remote monitoring, high-rate therapy for arrhythmias, or data-intensive diagnostics without draining the battery faster. The introduction of wireless power transfer would not only eliminate routine replacement surgeries but also enable more sophisticated devices that can be smaller, lighter, and implanted in anatomically favorable locations.

Wireless power also addresses a growing demographic challenge. As the global population ages, the number of patients receiving CIEDs is expected to rise sharply. The World Health Organization projects that by 2030, cardiovascular disease will remain the leading cause of death, and the demand for implantable therapeutics will increase accordingly. Reducing the need for repeated surgeries becomes a matter not just of convenience but of healthcare capacity and patient safety.

How Wireless Power Transfer Works for Medical Implants

The fundamental principle of wireless power transfer for implanted devices is the transmission of energy across the skin barrier without physical connectors. Energy is generated by an external source (transmitter) and captured by a receiver inside the body, where it is converted into electrical current to charge a battery or power the device directly. The key challenge is achieving sufficient power transfer efficiency while ensuring tissue heating remains within safe limits. Four main modalities have been investigated for cardiac implants:

Inductive Coupling

The most established WPT method uses magnetic induction. A primary coil outside the body generates an alternating magnetic field, which induces a voltage in a secondary coil embedded in the implant. Efficiency depends heavily on coil alignment and distance; typically, inductive coupling works best with a separation of less than 2 cm. For cardiac implants—often placed just under the skin in the pectoral region—this distance is feasible. Modern inductive systems can deliver 1–10 watts of power with efficiencies exceeding 70% under optimal conditions. However, misalignment due to patient movement or tissue shift can degrade performance. Researchers have developed adaptive coil configurations and automatic tuning circuits to maintain coupling efficiency in real time.

Inductive coupling is already used in some commercial systems for charging neurostimulators and cochlear implants. For cardiac devices, a 2020 study published in the IEEE Transactions on Biomedical Engineering demonstrated a prototype inductive system capable of recharging a pacemaker battery through 15 mm of simulated tissue with 85% end-to-end efficiency. The study concluded that with further miniaturization, such systems could be clinically viable within five years.

Resonant Inductive Coupling

By adding resonant capacitors to both transmitter and receiver coils, resonant inductive coupling improves efficiency and tolerance to misalignment. The system operates at a specific resonant frequency—typically in the range of 100 kHz to 10 MHz—allowing energy to be transferred more effectively across larger distances (up to 5–10 cm). For a cardiac implant, this means the external power source can be worn in a garment or placed on a bedside pad, giving the patient more freedom. Resonant coupling also reduces the sensitivity of the link to changes in the distance and orientation.

Several research groups have explored this approach for leadless pacemakers, which are small, self-contained devices placed directly inside the heart. Because leadless pacemakers have no leads extending to a subcutaneous generator, they offer a unique opportunity for fully wireless power. A 2022 paper in Nature Communications described a resonant system that delivered 200 mW of power to a 1 cm3 receiver at a depth of 4 cm, with tissue temperature rise limited to less than 1°C. The authors noted that further work is needed to ensure patient safety under chronic exposure to the oscillating magnetic field.

Radiofrequency Energy Transfer

Radiofrequency (RF) power transfer uses antennas to radiate electromagnetic waves at frequencies from 900 MHz up to several gigahertz. The implant contains a rectenna (rectifying antenna) that converts the received RF energy into DC power. RF methods can operate over longer distances—meters rather than centimeters—but suffer from significant attenuation in tissue, which is a lossy medium. As a result, the amount of power that can be safely delivered is limited to a few milliwatts, making RF transfer ideal for low-power sensors or as a trickle charge to extend battery life rather than for full-power device operation.

Researchers are investigating beamforming techniques and phased-array transmitters to focus RF energy on the implant, improving efficiency. A 2021 study from the University of Washington demonstrated an RF-powered cardiac monitor that harvested 100 µW continuously through 3 cm of tissue, sufficient for periodic telemetry but not for high-rate pacing. For defibrillators that require short bursts of high energy (up to 40 J), RF alone is insufficient; however, combining RF with a small rechargeable battery could offer a hybrid solution.

Ultrasound-Based Power Transfer

Ultrasound uses high-frequency sound waves (typically 1–10 MHz) to carry mechanical energy through tissue. An external piezoelectric transducer emits focused ultrasonic waves, which are received by a second piezoelectric element on the implant, converting the mechanical vibration into electrical energy. Ultrasound offers excellent power transfer through tissue with minimal heating, and it can be focused to deep structures such as the heart with high spatial precision. Unlike magnetic fields, ultrasonic waves are not subject to interference from metallic implants or MRI scanners, which is an increasing concern as more patients receive both devices.

The main limitation is that ultrasound requires good acoustic coupling and line-of-sight between the transmitter and receiver. Air pockets (for example, in the lungs) can block the beam, and the ribs can create shadowing. However, for subpectoral implants, a chest-wall transducer can maintain a consistent acoustic path. A 2023 review in Ultrasound in Medicine & Biology concluded that ultrasound WPT has the potential to deliver 1–10 W with efficiencies above 40% in ideal conditions, and several preclinical studies have shown feasibility for powering pacemakers and left ventricular assist devices. Work remains to develop efficient, miniaturized receiver arrays and to ensure long-term safety of chronic ultrasound exposure to cardiac tissue.

Key Advantages Over Traditional Battery-Powered Devices

Implementing wireless power transfer in cardiac implants confers benefits that extend far beyond eliminating battery replacement surgery:

  • Reduced surgical interventions. Removing the need for generator replacement means patients undergo fewer operations over their lifetime. This decreases cumulative infection risk, lowers the incidence of pocket complications, and reduces the burden on surgical resources. For pediatric patients, who may need dozens of replacements over a lifetime, this advantage is transformative.
  • Smaller device size and improved aesthetics. Current CIEDs are constrained by the battery, which occupies a large portion of the device volume. With a smaller or no battery, implants can be dramatically miniaturized. Leadless pacemakers are already approaching the size of a large vitamin capsule; wireless power could make them even smaller and suitable for implantation via catheter in a minimally invasive procedure.
  • Enhanced functionality. Continuous power enables always-on monitoring, advanced diagnostics, and data-intensive features such as real-time arrhythmia detection with high-resolution electrograms. Devices could also support software updates and new therapy algorithms over the air, much like smartphones, without worrying about battery drain.
  • Improved patient safety and quality of life. Patients no longer need to undergo repeated pre-operative assessments, hospital stays, or recovery periods. The psychological burden of knowing a device will need replacement is eliminated. Additionally, wireless power opens the door to truly remote device management, where a patient can recharge their implant from a wearable vest or pad while sleeping.
  • Lower lifetime healthcare costs. Although wireless charging systems add upfront expense, the elimination of replacement surgeries, associated complications, and hospitalizations is projected to produce net savings. Health economic models estimate a 40–60% reduction in lifetime device-related costs for pacemaker patients if wireless power becomes standard.

Current State of Research and Clinical Trials

The field is moving rapidly from benchtop demonstrations toward clinical-grade systems. Several universities and medtech companies are developing proprietary wireless power platforms. For instance, researchers at the University of California, Los Angeles, have built a fully implantable wireless power system for ventricular assist devices that uses a resonant inductive link and a flexible receiver coil that conforms to the device shape. Their work, published in Nature Biomedical Engineering in 2023, showed that the system could deliver 15 W continuously through a porcine chest wall with a temperature rise under 2°C—a critical safety margin.

Another notable effort comes from Karolinska Institute in Sweden, where a team has developed an ultrasound-powered leadless pacemaker that harvests energy from a transducer placed on the skin. In a 2022 proof-of-concept animal study, they successfully paced a rat heart at physiological rates using only ultrasound energy, with no onboard battery. The group is now working on scaling the system for human-sized hearts and securing funding for first-in-human trials.

On the commercial side, WiTricity Corporation—known for its work in electric vehicle charging—has licensed its resonant coupling technology to a major cardiac device manufacturer. While details remain confidential, the partnership suggests that a clinical-grade system could be undergoing feasibility studies. Similarly, Medtronic and Abbott have publicly expressed interest in wireless power for leadless pacemakers and neurostimulators, filing numerous patents for novel receiver architectures and safety circuits.

Regulatory hurdles remain significant. The U.S. Food and Drug Administration (FDA) requires rigorous testing to ensure that chronic exposure to electromagnetic fields does not cause tissue heating, nerve stimulation, or interference with other implanted devices. Recent FDA guidance on wireless medical devices suggests a pathway that includes electromagnetic compatibility testing and thermal modeling. As of mid-2025, no wireless-powered cardiac implant has received market approval, but several are expected to enter pivotal clinical trials within the next three years.

Future Outlook and Remaining Challenges

Despite substantial progress, several obstacles must be overcome before wireless power becomes standard for cardiac implants:

Safety and Thermal Management

Delivering even a few watts of power through skin inevitably causes some tissue heating. The threshold for thermal damage is around 6°C above body temperature, but regulatory limits are more conservative—typically restricting temperature rise to 2°C. Adaptive power control algorithms can modulate the transmitted power based on real-time temperature sensors, but these add complexity. Future designs will likely integrate active cooling (e.g., microchannel heat spreaders) or use duty-cycled bursts to allow tissue to dissipate heat.

Interference and Electromagnetic Compatibility

Cardiac implants must work reliably in the presence of MRI scanners, diathermy equipment, and other medical devices. Wireless power transmitters generate strong electromagnetic fields that could induce currents in leads or disturb the implant's sensing circuits. Newer leadless designs reduce this risk by eliminating leads, but careful shielding and frequency planning are needed. The Medical Implant Communication Service (MICS) band at 402–405 MHz offers a potential coexistence strategy if power transfer can use a separate frequency.

User Adoption and Daily Wearability

For daily charging, the patient must wear or sleep with an external transmitter. This requires a power source (e.g., a battery in a vest, a charging pad on the bedside table) that is convenient and reliable. Engineers are exploring inductive garments that can be worn like a chest strap, but comfort, hygiene, and compliance remain concerns. Some research groups have proposed using ambient energy harvesting from body motion or thermal gradients, but these provide only microwatts—insufficient for active pacing. A hybrid approach, combining a small primary battery with occasional wireless boost, may be the most practical bridge solution.

Miniaturization and Cost

Shrinking the receiver circuitry to fit inside a 2-mm thick device while maintaining >50% efficiency is a non-trivial materials and manufacturing challenge. Advances in gallium nitride (GaN) power amplifiers and flexible printed-circuit-board coils are bringing the costs down, but the added components will initially raise the price of each implant. Economies of scale and competition are expected to reduce the premium over five to ten years.

Looking further ahead, wireless power could enable entirely new classes of cardiac devices: bioresorbable pacemakers that dissolve after a few months, injectable microstimulators for targeted therapy, and closed-loop systems that deliver energy on demand from an external source worn as a patch. Integration with sensor networks and artificial intelligence could allow the device to predict arrhythmias and preemptively receive power for rapid pacing or defibrillation. The ultimate goal is a seamless, battery-free implant that operates for the patient's entire lifetime without intervention.

As research continues, the convergence of efficient power transfer, smart materials, and regulatory clarity will push wireless power from an experimental curiosity to a standard of care. The next decade will likely see the first clinically approved systems enter the market, initially for leadless pacemakers and eventually for all cardiac implantable devices. For patients, that future means one less surgery to worry about—and a quality of life that is no longer measured in battery cycles.